

The infant gut microbiota: in pursuit of non-protein nitrogen

Patrick Schimmel^a, Bernd Stahl^{b,c}, Jan Knol^{a,b}, and Clara Belzer^a

^aDepartment of Agrotechnology and Food Sciences, Wageningen University & Research Center, Laboratory of Microbiology, Wageningen, The Netherlands; ^bDanone Nutricia Research, Utrecht, The Netherlands; ^cDepartment of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

ABSTRACT

Diet shapes our gut microbiome from the day we are born. The contribution of dietary non-protein nitrogen to normal and healthy nitrogen cycling in the infant gut is scarcely described. Herein, we review in vitro and in vivo findings that show the impact of Human Milk Nitrogen (HMN) on the gut microbiota that colonizes the gut in early human life. We describe that several non-protein nitrogen sources, that include creatine, creatinine, urea, polyamines and free amino acids, are key in establishing the bifidobacterium-dominated microbiome and thus are bifidogenic. Furthermore, several parts of HMN-related metabolism are associated with a healthy infant gut and commensal microbiota. We illustrate an overlap and great diversity in accessibility of HMN by large parts of the infant gut microbiota. This review nonetheless shows the importance of research on HMN and its effects on the activity and composition of the infant gut microbiota and its potential effect on early life infant health.

ARTICLE HISTORY

Received 21 June 2022
Revised 3 May 2023
Accepted 4 May 2023

KEYWORDS

Human; milk; nitrogen; breastfeeding; infant; gut; bacterial; metabolism; microbiome; health

Introduction

The human gut contains a microbial cell population, or microbiome, that through its presence and activity supports human immunology and prevents disease.¹ This microbial support in our gut starts immediately after birth and is efficiently supported by human milk (HM).^{2,3} Early life provides a unique opportunity to study the effect of diet on microbiota. Even though the process of defining a healthy infant microbiota is ongoing, we understand that breastfeeding promotes a *Bifidobacterium*-dominated microbiome in healthy infants.^{3,4} However, variations in microbiota composition, geographically and inter-individually are high.^{2,5} Nonetheless, breastfed infants are considered a low-risk group for many health threats,^{6,7} thus making breastfeeding the golden standard for infant feeding. This guided research toward identifying prebiotics in HM that promote a beneficial microbiota. Fundamentally, to understand metabolism in the breastfed infant's gut and more applicably to improve infant feeding alternatives. Therefore, a recent research focus was the bacterial acquisition of carbon in the infant gut. Human Milk Oligosaccharides (HMOs), a dominant carbon source in HM, are

selectively utilized by *Bifidobacterium* spp. and are therefore promoting *Bifidobacterium* spp. in the infant gut environment.^{8–10} HMOs are not the only nutrient class in HM, and the bacteria have likely adapted to other molecules and nutrients present. Moreover, nitrogen is a fundamental need for bacteria to survive in any environment. This suggests that implementing oligosaccharides in the infant diet alone will not lead to a sufficient resemblance to a breastfed microbiota.^{5,11}

An equally crucial pinnacle of survival for bacteria in the infant gut is not well documented, namely the acquisition of nitrogen. Meanwhile, research shows that microbial communities are profoundly affected by nitrogen availability.^{12,13} Breast milk is a complex bio-fluid and holds a thorough co-evolution orchestrated nitrogen content. While containing relatively low amounts of protein compared to the diet in later life, it has various other sources of nitrogen including secretory waste products of human metabolism, amino acids (AAs), polyamines and vitamins.^{6,14–23} The evolution of HM and a co-evolving microbiome makes it likely that the microbiota of the breastfed

CONTACT Clara Belzer  clara.belzer@wur.nl  Department of Agrotechnology and Food Sciences, Wageningen University & Research Center, Laboratory of Microbiology, Stippeneng 4Helix Building, Wageningen 6708 WE, The Netherlands

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

infant is adapted to low protein concentrations is utilizing this specific nitrogen supply to gain a competitive advantage. The rapidly developing human infant is in high demand for nitrogen as well, sketching a vital and delicate balance between host and gut microbiota.

Many gut symbionts can incorporate ammonium (NH_4) since most gut bacteria possess the capability to produce a glutamate dehydrogenase and use ammonium in their biosynthetic pathways. Not surprisingly, this usage of ammonium has proven to be one of the most dominant microbial pathways expressed in the infant gut microbiome.² This is important for detoxification, since high levels of ammonium can be detrimental to both microbiota and host.²⁴ It can therefore be hypothesized that this is the most common source of nitrogen available in the gut and that microbial metabolism centers around ammonium.²⁵ Ammonium itself is interestingly enough only present in trace amounts compared to other HMN sources.²⁶ We suspect that the infant gut microbiota catabolizes other nitrogenous compounds to acquire and share ammonium.

This review focuses on microbiome interactions with dietary nitrogen in the infant gut, during the first months of life, particularly with HMN sources. However, infant absorption of many of these components should be considered and is currently elusive. It is unknown exactly how much of the tailored non-protein nitrogen content reaches the colon and is accessible to the microbiota. However, since HM provides such a tailored nutrient input, hypotheses can be formed on how nitrogen is salvaged by the microbiome. A surge in expressional and metaproteomic studies provides information about which bacteria are actively metabolizing in the infant gut. This data contributes to our understanding about which bacterial metabolic pathways are active in early life. This is especially relevant since a functional characterization of nitrogen metabolism is often lacking, while its importance for understanding the gut microbiota has been suggested.²⁷ By linking the bacterial genomes, microbiomes *in vitro* findings of active symbionts to dietary input, new avenues for scientific experimentation can be found. Later, these findings can be used to directly link metabolism surrounding HMN to infant health and development.²⁸ The

nitrogen sources considered in this review are the mother's secretory waste products, free AAs, polyamines, nitrate and nitric oxide (NO) and nitrogen from HMOs which are all featured in HM.

Sizeable efforts have been made to describe the composition of infants' gut microbiota through 16S rRNA sequencing,^{2,5,29} and later through functional profiling with metagenomics, metaproteomics and metatranscriptomics.^{2,30–33} Potential functions and their relative occurrence have led to theories on what the microbiota is doing in early life. Furthermore, descriptive studies of infant gut bacteria are included to describe the potential of highlighted bacteria to interact with HMN sources. Combined, the included studies provide information on the bacterial genera *Bifidobacterium*, *Enterococcus*, *Escherichia*, *Bacteroides*, *Enterobacter* and *Streptococcus* and on their interactions with HMN during the first 6 months.

Breast milk derived secretory nitrogen-containing waste products

Secretory waste products, such as urea, creatinine and creatine, deriving from the mother's metabolism end up in the breast milk.^{14,15,17} Currently, there is no known biological reason for the occurrence of urea, creatinine and creatine in HM. However, gene content related to nitrogen metabolism of the infant gut microbiota has been shown to be responsive to diet.^{27,34} If a supportive microbiome is dependent on receiving these compounds through breast milk, related nitrogen metabolism could prove crucial to our understanding of the early life colonization of the microbiome, especially considering the sensitive development of the gut microbiota during infancy.

The potential role of urea in the early life microbiota

Urea is the most abundant non-protein nitrogen compound in HM. Urea constitutes up to 15% of total nitrogen in HM.^{15,18,22,35} The human body is incapable of degrading urea through endogenous enzyme production. Urea is a product of human liver metabolism that constitutes of two amine groups connected by a carbonyl group and it is for the largest part secreted through urine production. In lesser extent, urea is secreted in human

milk and in the gut. Bacterial Urea Nitrogen Salvation (UNS) has often been suggested as being important for infant gut nitrogen cycling.^{15,34,36,37} Urease (EC3.5.1.5) is the first bacterial enzyme ever described.³⁸ It is widely spread across the bacterial kingdom and is especially known as a virulence factor for human pathogens. Regulation and activation of this enzyme have been studied in those pathogens. For example, nickel chelation is required for enzyme activation when studying urease activity in pathogen model systems like *Helicobacter pylori* and *Klebsiella aerogenes*.^{39,40} On the contrary, urease has been indicated as a health-associated factor.⁴¹ As the input metabolite, urea can derive from bacterial metabolism due to bacterial arginase activity.⁴² In *Bifidobacterium infantis* (*B. infantis*) it seems that urease activity is limited to the presence of urea.³⁴ Urease is involved in microbial amino acid metabolism, yet has also been indicated as a pH regulator as part of an acid response, for intestinal bacteria.^{43–45} This is especially important, since the healthy range of pH in the infant colon is considered between 4.5 and 5.5 with *B. infantis* present.⁴⁶

Bacteria removing urea from the infant gut can be crucial to infant health since liver and kidney systems are underdeveloped compared to adult life.^{47,48} In an adult human host, health status determines the availability of urea in the gut and that subsequently increases urease activity.^{41,49,50} Clearly, urea is also available to the bacterial infant gut colonizers during early life, of which human milk is the major source. Besides originating in breast milk, it is likely to also be secreted into the gut lumen by the neonatal host, as with adults. Notably, in the early days of infant gut studies, it was shown that the urea fecal output is lower than the estimated input through breastfeeding, indicating urea processing in the gut. Furthermore, 15N isotope studies in humans showed assimilation of urea into AAs.^{51,52} Interestingly, microbial nickel transporters were found to be abundant during early life,³³ which are required as a cofactor for urease enzyme activation. Notably, nickel is found in HM at levels between 1.0 and 51.0 µg/L across studies.⁵³ Furthermore, there is evidence that the potential of urease activity relates to the microbiome of breastfed infants. As such, urease genes

and the enzymatic activity are more abundant in exclusively breastfed infants.^{5,35}

Interestingly, urease activity is linked to amino acid metabolism and thus the acquisition of nitrogen for synthesis in bacterial gut species. Specifically, urease activity was shown in *Streptococcus thermophilus* to be associated with amino acid synthesis and cell growth.^{54,55} Furthermore, *Bifidobacterium* spp. have shown to be urease active.^{34,56} However, it is also clear that not all *Bifidobacterium* are able to access urea as nitrogen source. Urease-active bifidobacteria might, however, prevent pathogens from utilizing this urea. The opportunistic pathogen group of *Enterococcus* spp. have been associated with luminal urease activity, for example.⁵⁷ Notably, *Enterococcus* spp. colonization of the infant gut negatively correlates with infant health status.³² *Enterobacteriaceae* is an interesting group when considering urease activity,⁵⁸ as well as *Escherichia* spp. that occur in the early life human gut.^{59,60} Finally, *Bacteroides* can be the genus that profits from urea in mature HM. For example, *Bacteroides koreensis* sp. nov. and *Bacteroides kribbi* sp. nov., two new members of the genus *Bacteroides*.⁶¹ Importantly, urease activity might be a way to survive in an acidic environment when fatty acid production is high. How nitrogen is further cycled by bacteria is still unclear, although the resulting ammonium should be a suitable nitrogen source for many other microbes in the environment. Thus, both beneficial bacteria and potentially infectious or harmful bacteria are potentially competing over breast milk urea. This competition over urea with commensals prevailing might be crucial for a healthy microbiome.

The potential role of creatinine in the early life microbiota

Both creatine and creatinine are transported into HM. Measured creatinine concentrations in HM vary greatly, but it was early established in the ±41–65 µM range.⁶² Infant formula often contains higher levels of creatinine, due to its origins in cow's milk.^{62,63} Creatinine originates in a human host as a secretory product of muscle use and repair.^{64,65} It is stored as phosphocreatine locally,

to provide plenty of phosphate for human energy metabolism and specifically ATP.⁶⁶ It is most abundant in skeletal muscle as a reservoir for active outbursts by the host. During muscle metabolism, creatine turns into creatinine in an endogenously irreversible reaction. This creatinine will then be secreted from the host and functions as a biomarker in urine, blood and human milk. Clearing breast milk creatinine by the early life gut microbiome could impact neonatal gut health.

During life, creatinine will likely be available to the gut microbiome, especially during periods of low kidney functioning. Just as during early life, when kidney and other secretive functions of the human body are hindered or still in development.^{47,67–70} However, it is unclear how much creatinine is secreted in the infant gut by the host. Creatinine degradation occurs through bacterial creatininase activity wherever creatinine is available.^{64,71,72} This occurs via three routes: 1) a combined effort of creatinine iminohydrolase (creatinine deaminase; EC 3.5.4.21) and a cytosine aminohydrolase (cytosine deaminase; EC 3.5.4.1); 2) creatinine amidohydrolase (creatininase; EC 3.5.2.10); 3) and finally a less characterized route via creatol and methylguanidine (Figure 2).⁶⁴ A major product of creatinine degradation via creatinine deaminase is 1-methylhydantoin, an intrinsic hydroxyl radical scavenger or antioxidant.^{73,74} The use of ¹³C-labeling to prove that creatinine is oxidized by mammals into creatol and 5-hydroxy-1-methylhydantoin.⁷⁴ Specific genes involved in this metabolism are hardly characterized by common infant gut symbionts. However, the infant gut microbiota gets a chance of interacting with this nitrogen source in early life.

For every HMN source, we studied its potential in selecting for a health-promoting microbiota. Creatinine is negatively correlated with the abundance of *Bifidobacterium* spp. during the first month of life, indicating a role for the genus in a detoxing effect.⁷⁵ This was confirmed when applying a mixture of *Bifidobacterium* spp. and *Lactobacillus* spp. led to lower creatinine levels in broiler chickens, although the opposite has also been shown in broiler chickens.^{76,77} Therefore, the fate of creatinine in infant gut nitrogen cycling remains elusive. A possible explanation for the conflicting observations can lie in microbiota

composition and activity. Perhaps it diffuses into the intestinal tract, to be degraded by the gut microbiome or to be secreted through urine. In the gut, through bacterial metabolism more creatine can become available for the bacteria, so creatine should be considered a potentially important part of HMN.

Creatine (Cr) is provided by HM in concentrations around 77 μ M, while others established it at slightly lower concentration.^{62,78} In HM, there was no observed difference between Cr concentrations at 1–2 week postpartum and 5–6 weeks. Interestingly, the formula seems to hold higher concentrations of creatine (>4 \times), while others are almost deprived of it.⁷⁸ The milk source of these formulas is explaining these levels, with, for example, cow's milk being rich in Cr. Notably, guanidinoacetate (GAA) is the precursor of Cr in the human body. Edison *et al.* 2013 established, however, that HM is not a clear route of supplying infants with GAA, since a clear presence is lacking.⁷⁸ Interestingly, calculated from intake and an estimated size of the Cr pool in infants, 90% of creatine should originate in endogenous production from energy metabolism and muscle use, which potentially cycles into the intestine.

Creatine functions in bioenergetics for neurological and muscle cells by maintaining ATP levels.^{64,79} A Cr pool exists in the human body to maintain homeostasis in this concern, together with creatine phosphate that can accumulate up to approximately 100 g.^{62,64} As mentioned, creatine is linked to the availability of creatinine as well. Creatine kinase (EC 2.3.7.2) transforms Cr into phosphocreatine, a crucial step in human body energy homeostasis. Creatine kinase is, traditionally, an indicator of health⁸⁰ and that might be impacted by bacterial Cr metabolism in the neonatal gut. Furthermore, there are a few indications that high Cr is associated with infant fed formula.^{81,82} Bacteria that are capable of degrading Cr in the human gut have been identified.⁸³ First indications of association of creatine with microbiome composition also exist.⁸⁴ It was shown that Cr negatively correlates with *Bifidobacterium* spp. and positively correlates with *Klebsiella* spp., further indicating the potential for a microbiome dominated by bifidobacteria to have a higher potential for clearing Cr.⁸⁵ Furthermore, probiotic

supplementation of *Bifidobacterium lactis* has been shown to alter Cr amounts in rats indicating an improved energy metabolism for the host.⁸⁶ Finally, in the aging mice gut, Cr availability led to an increase in creatine degradation occurrence in the functional profile of the gut.⁸⁷

Polyamines and their impact on the infant gut microbiota

Polyamines (PAs) are, under physiological pH, polycationic substances, rich in nitrogen that function in human cell growth and tissue maturation. These biogenic amines can therefore be in high demand for rapidly growing tissues, like the developing gastrointestinal tract of the newborn.^{21,88,89} Moreover, PAs are suggested to be involved in immune system maturation, functioning and modulation of gut permeability.^{90–93} In HM, occurring PAs are spermine, spermidine, putrescine and cadaverine all have two or more amino groups.⁹⁴ PAs can derive from either host and bacterial metabolism or diet. The fact that PAs are rich in nitrogen makes it an interesting nutrient source for the colonizing microbiome. In HM, polyamine concentrations increase postpartum^{19,20,95} with concentrations collapsing from the second month onwards.^{19,21,96} Gómez-Gallego *et al.* investigated polyamine concentrations in HM of healthy mothers. The most abundant was spermine (6.1 μM), followed by spermidine (4.2 μM) and finally, in lesser amounts, putrescine (0.7 μM), with slight variation due to geographic locations in spermidine and putrescine. It was, however, established early that concentrations vary greatly between mothers.¹⁹ Buts *et al.* (1995) established a similar polyamine profile in HM samples (spermine, 3.1 μM ; spermidine, 2.2 μM ; and putrescine, 0.24 μM) with a total polyamine concentration of 5.57 μM (± 0.18 μM).⁹⁷

The availability of polyamines in the infant colon is currently enigmatic. According to current knowledge, most PAs are, however, absorbed in the upper intestine in support of growth processes of the human body.⁹⁸ In the infant GI-tract, however, optimal adsorption might be developing in combination with a large supply through HM, causing polyamines to reach the colon. PAs occur in the

colon of healthy adults within the range of 0.5 to 1 mM.⁹⁹ There, PAs are adsorbed into the human body through the colonic mucosa.¹⁰⁰ In the colon, bacteria are suggested to be largely responsible for the PAs present there. Bacteria can produce a wide range of PAs, including spermidine, homospermidine, sym-homospermidine, norspermidine, putrescine, cadaverine and 1,3-diaminopropane, while there are also bacteria that are not able to produce any.^{101,102}

Synthesis of polyamines is mainly regulated and activated by ornithine carboxylases.¹⁰³ These carboxylases catalyze the decarboxylation of ornithine to produce putrescine. Followed by several methods of elongation, for example spermidine synthase (EC 2.5.1.16), while in the meantime adding one or two more amine groups originating from other nitrogenous compounds (Figure 1). For a long time, biosynthesis of polyamines was mainly studied in *Escherichia coli* (*E. coli*) of which related spp. also occur in the infant gut, albeit as a minor component.²⁹ More common microbiome members in the first 2 months of life, e.g. *Streptococcus* spp. and *Enterococcus* spp. have been shown to produce polyamines from AAs.¹⁰⁴ This enzyme is broadly studied in *Bacteroides* spp.^{105,106} More recently, activity of a carboxyspermidine decarboxylase (*casdc*) was described in *Bacteroides thetaio-taomicron*, a representative of a genus highly present in many life stages, including infancy. This *Bacteroides* strain produces the polyamine spermidine in a polyamine free medium and moreover this that activity provided a growth benefit for the strain under these conditions.¹⁰⁷ This provides an indication of polyamine metabolism potentially selecting for bacteria in a complex microbial environment. In HM, however, the longer polyamines are more dominant than its precursors (Figure 1).

Polyamines might also provide a health benefit through gut microbiome modulation, and first evidence has been provided.¹⁰⁸ In mice, supplementation of PAs in formula led to a significant increase of *Bifidobacterium* spp., *Bacteroides* spp., *Clostridium* spp. and *Verrucomicrobia* spp. (as “Akkermansia-like bacteria”) in the large intestine. *Bifidobacterium* spp. were even higher than breastfed pup-mice. Interestingly, polyamine supplementation led to the promotion of autophagy in human cell lines, an




Figure 1. A representation of the important bacterial processes surrounding human milk nitrogen in the colon (HMN) and which bacterial genera are involved, concerning 6 nitrogen sources: Urea, Creatine (Cr)/Creatinine, Polyamines, Glutamate/Glutamine, Other Amino Acids (AAs), Nitrate. Absorption of components by host likely occurs in the small intestine. Hexagons represent relative abundance of components in HM. Abbreviations: assoc. = associated; corr. = correlated; metab. = metabolism; prod. = production; antib. = antibiotic.




Figure 2. A representation of creatine and creatinine metabolism with pathways important for the infant gut as described above; Abbreviations: creatine (Cr), creatine kinase (CK), guanidinoacetate (GAA).

indicator of gut health which inhibited the propagation of SARS-CoV-2.¹⁰⁹ Since autophagy plays a role in gut barrier maintenance, polyamine as a part of our diet can have a health impact.¹¹⁰

Here, we summarize the understanding of polyamine metabolism by infant gut bacteria. There is no current evidence of extracellular degradation of polyamines by gut bacteria. However, within the *Bifidobacterium* genus the capability to synthesize and transport polyamines to the intracellular environment has been reported¹¹¹. With spermidine *in vitro*, spermidine is absorbed by the bacteria and in some cases is processed (*Bifidobacterium scardovii*).¹¹¹ No known homologs were detected, indicating a possibility for novel methods of polyamine processing in *Bifidobacterium* spp. Spermine, the longest naturally occurring polyamine in HM, was taken up by more *Bifidobacterium* strains in the study by Sugiyama *et al.*¹¹¹ Again, the system of choice for this type of transport, a *potRABCD* transport system, was not found in the genus.^{111,112} Moreover, extracellular concentrations of spermine were increasing during growth phase of, among others, *B. infantis*. Also, *Bifidobacterium adolescentis* (*B. adolescentis*) was proven to export spermidine into the supernatant *in vitro*.¹⁰⁴ The production of putrescine from ornithine seems to be prevalent in many species of the *Bacteroides* genus. For example, *Bacteroides fragilis* has been noted as possessing this capability with the goal to produce γ -aminobutyric acid (GABA).^{113,114} Most studies have shown that cultural conditions tend to be highly specific for strains, leading to low replicability. However, this is a promising mechanism by which the infant gut microbiota promotes health during early life. Especially, since initial evidence showed that polyamine supplementation in formula

counteracts allergy occurrence and gut permeability issues.⁹³ However, bacterial metabolism concerning polyamines has hardly been considered to play a role in infant health. According to the literature reviewed here, polyamines are bifidogenic. It makes this part of HMN interesting for future study.

AA metabolism & the GABA shunt

Both bacterial protein fermentation and human digestion can lead to the liberation of amino acids (AAs). Before that, proteases produced by the mother digest human milk protein.¹¹⁵ This review highlights that the commonly released AAs are at the core of bacterial metabolism and their survival.¹¹⁶ Where there are AAs, bacteria multiply. This review proposes that the infant gut is not any different. If the first meals to pass through the newborn's GI-tract are developed to kick-start bacterial metabolism, AAs might be key.

The role of glutamate, glutamine for the infant gut microbiota

The amino acid glutamate, however nutritionally nonessential, plays a role in many important metabolic processes, including the citric acid cycle, protein synthesis and acts furthermore as a precursor for several bioactive compounds.^{117,118} Glutamate is the most dominantly occurring free amino acid in HM, only closed by its close relative glutamine. Glutamate as a dominant dispensable free amino acid occurs in the range of 960.1–1529.0 μ M, reaching peak supply at 4 months into the lactational period. However, a higher concentration of 4.5 mM has been argued.^{6,14,119,120} Free glutamate is

during this period proportional to the amount of glutamate supplied through protein, in which glutamate is also the most dominant AA.¹²¹ This level of free glutamate is significantly higher than the level found in the average cow's milk-based formula.^{120,122} Interestingly, it is also higher than the 30 mg/kg BW (0.204 mmol/kg BW) per day acceptable daily intake (ADI) of free glutamate set by the European Food Safety Authority for infants, due to neurotoxicity concerns. An infant weighing 5 kg receiving a recommended 0.75 L of human milk would, according to that standard, only receive 0,76 mmol (1,02 mM) of free glutamate. Breastfeeding being the infant feeding method of choice makes it likely potential health benefits underly the presence of these levels of glutamate. Bacterial interaction in the infant gut with glutamate is likely a very prominent part of infant gut nitrogen cycling.

Glutamate catabolism is achieved through glutamate dehydrogenase (GDH) or glutamate decarboxylase (GAD, Figure 3). The GDH enzyme leads to the assimilation of ammonia into AAs, with glutamate as the starting point. Glutamine synthetase (GS) catalyses the reaction of glutamate to glutamine.^{117,123} Glutamate metabolism can be part of bacterial stress responses, including acid responses.¹¹⁸ Glutamate decarboxylase is involved in acid stress response, causing decarboxylation of glutamate to γ -aminobutyrate (GABA). GABA is the main inhibitory

neurotransmitter, while glutamate, its precursor, is the main excitatory neurotransmitter.^{124,125} Bacteria can then export it through a GadT2 Glutamate/GABA antiporter, after which is absorbed into the human body, providing benefits for health and development in the nervous system.^{126,127} Notably, the human body can convert glutamate through GAD-activity, hence the high demand of glutamate for the infant body and its developing nervous system. Interestingly, a ferredoxin dependency occurs in the GABA-shunt via dependency of the glutamate synthase.¹²⁸ This enzyme catalyses the production of glutamate from 2-oxoglutarate and glutamine as nitrogen source. However, ferredoxin metabolism is not commonly studied in the infant gut. Physiologically, an external supply of glutamate could replace a need for endemic production of this amino acid. In the developing human body glutamate serves a wide array of purposes in neurology and energy homeostasis. Bacteria-wise, a metaproteomics study by Xiong *et al.* showed that among conserved functional groups was glutamate dehydrogenase, in all studied infants.³⁰ The importance of glutamate is furthermore indicated by the fact that it is almost completely metabolized first pass in infant pigs. Such a scenario is likely in the human infant gut as well.¹²⁹

There is evidence for glutamate metabolism by bifidobacteria.¹³⁰ All included *Bifidobacterium* strains (*Bifidobacterium breve*, *Bifidobacterium*




Figure 3. A representation of glutamate metabolism by both bacteria and the human host as an important nitrogen cycle for the early life gut. Abbreviations: glutamine synthetase (GS), glutamate dehydrogenase (GDH), glutamate decarboxylase (GAD), γ -aminobutyrate (GABA).

longum subsp, *Bifidobacterium pseudolongum*, *B. adolescentis*) showed both synthetase and dehydrogenase activity for all, although at different levels.¹³⁰ Interestingly, lower Km values for the glutamate synthetase of *Bifidobacterium* spp. compared to almost every other included strain except a *Lactobacillus* sp., indicating that *Bifidobacterium* is an efficient genus in detoxifying the infant gut from ammonia. Indicating a key role for *Bifidobacterium* spp. in glutamate cycling, the purified GS of *B. bifidum* reacted optimally in an acidic environment, which was not the case for the non-*Bifidobacterium* spp.¹³¹ This would match the infant gut's acidic conditions. Glutamine and glutamate cycling by *Enterococcus* and *Streptococcus* spp. has been studied, but in the small intestine of ruminants or in the bird gut.^{132,133} Finally, the production of GABA from glutamate as an important metabolic route should be investigated. *E. coli* was one of the organisms in which it was shown that GABA metabolism conferred acid resistance in bacteria.¹³⁴ Recently, The production of GABA has been contributed to more common infant gut symbionts like *Bacteroides* spp.¹¹⁴

Other predominant amino acids: Taurine and Cysteine

Taurine or aminoethylsulfonate (a C2 sulfonate) is a sulfur-containing amino acid in HM. Taurine is the third most dominant-free amino acid in HM.^{16,17,135,136} Moreover, the infant's body can synthesize taurine but not degrade it, making plenty of the amino acid available for microorganisms. Namely, a large portion of taurine is secreted from the human body in the form of taurine-conjugated bile salts.¹³⁷ This requires the release of taurine by bile salt hydrolases by bacteria. One of those genera is *Bacteroides*.^{138,139} Fermentation of taurine is dependent on the cleavage of the inert sulfonate C-S bond.¹⁴⁰ A process not commonly described for anaerobic human gut bacteria, even though it is closely linked to the production of H₂S, toxic to the human body. Moreover, when it does occur, like *e.g.* in *E. coli*, it concerns a process involved in aerobic growth.^{141,142}

There is a diverse range of strategies for cleaving the C-S bond, yet not all are anaerobically feasible. Among the known pathways is a thiamine pyrophosphate-dependent sulfoacetaldehyde acetyltransferase system (Xsc) which occurs under both aerobic and anaerobic conditions.^{140,143} Further anoxic options are still poorly understood. One of the more remarkable is the description of an IseG-dependent system, where also L-alanine can be produced, in opportunistic pathogen *Bilophila wadsworthia* and *Desulfovibrio piger*.¹⁴³ Collard *et al.* went further and described taurine and its related physiological processes as key contribution to resistance to new infections.¹⁴⁴ In another study, taurine alone did not alter immune responses in the lamina propria.¹⁴⁵ However, it did affect gene expression in epithelial cells and, more interestingly, it showed the importance of a taurine trained microbiota. That led to a greater systemic resistance against *Klebsiella pneumoniae* and lower oxygen availability.¹⁴⁵ The relation to oxygen makes it so that the lack of a taurine-trained microbiota could lead to more potential for opportunists to colonize, like *Enterococcus* spp., a common pediatric infection source in the neonatal period. In another study, a healthy infant control group showed significant higher levels of taurine metabolism through a metagenomic approach, confirming a role in the healthy infant's metabolism.¹⁴⁶⁻¹⁴⁸ Targeting of taurine utilizers can benefit options for infant health care and nutrition.

Cysteine is another amino acid in HM that is potentially important to the microbiome. The biosynthesis of the amino acid cysteine serves to incorporate inorganic sulfur into organic matter.¹⁴⁹ Cysteine then plays a crucial role in many catalytic sites of subsequent protein and protein folding by being part of disulfide bonds.¹⁵⁰ Interestingly, bifidobacteria as dominant colonizers of the gut seem to be auxotrophic for the amino acid.¹⁵¹ *B. bifidum* (multiple strains) has shown reduced growth only when cysteine is lacking in an evaluation of auxotrophy across AAs occurring in HM.¹⁵¹ Cysteine metabolism has also been indicated as a key

metabolite that inhibits gut-related oxidative stress.^{152,153} Conclusively, both these AAs need to be considered in relation to infant feeding and the infant gut microbiota (Figure 1).

Breast milk derived nitric oxide, nitrate & nitrite

Nitric Oxide (NO) is involved in physiological processes in the gut that can determine an individual's health.^{27,154,155} Nitric oxide is synthesized from L-arginine by a nitric oxide synthase (NOS) and is involved in vasodilation, neurotransmission, the immune system, gene expression and regulation. Notably, NO is involved in triggering of lactation and might, for that reason, be featured in HM.¹⁵⁶ Notably, NO occurs in HM and concentrations peak in the first week postpartum.¹⁵⁷ Furthermore, it seems to be important for the oxidant and antioxidant status of human breast milk during lactation period.¹⁵⁸ The role of NO for the microbiota is currently elusive, but it might have a function that is lacking from the gut of infants fed formula products.¹⁵⁹ Interestingly, NO is involved in interactions between bacterium and host.¹⁶⁰ However, NO synthesis by bacteria in the infant gut, which handles oxidative stress, electron transport or antibiotic tolerance by the strains, can potentially be harmful as well.¹⁶⁰

In healthy adults, 1/3 of dietary nitrate ends up in the lower intestine, but only up to 1% ends up in the feces.¹⁶¹ Nitrate can provide a growth advantage for strains belonging to the genera *Escherichia*, *Bifidobacterium* spp. and *Lactobacillus* spp. under anaerobic conditions and low oxygen conditions (Figure 1).¹⁶² Furthermore, nitrate is an electron acceptor when oxygen is limiting, a realistic scenario in the infant gut a few week postpartum.^{162–165} *E. coli* even possesses three nitrate reductases that are active under anaerobic conditions.^{162,166} Nitrite can be toxic at higher concentrations and is therefore excreted to the environment. Interestingly, a study by Tiso & Schechter showed that *in vitro* culturing of infant gut symbionts produces large amounts of fatty acids and the subsequent acidification drives nitrite disproportionation to NO.¹⁶² To our current knowledge, *Bifidobacterium* spp. do not possess

enzymes to produce NO from nitrite. However, an environment dominated by *Bifidobacterium* spp. could theoretically produce levels of NO that affect gut health and integrity because of their role in the acidification of the environment.

The role of Nitrogen from Human Milk Oligosaccharides and other glycoconjugates for the infant gut microbiome

Human Milk Oligosaccharides (HMOs) are indigestible carbohydrate structures in amount and complexity unique to the milk composition of us humans. HMOs are the third most dominant carbohydrate source (after lactose and fat) available to the microbiome, occurring as high as 15 g/L.^{167,168} Especially so, since the infant is incapable of degrading these complex polysaccharides and only small amounts will be absorbed intact and thus they will reach the colon largely unscathed.^{169,170} So far, proven prebiotics such as galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) have been used in infant nutrition. In recent years, the first synthetic HMO structures are available. The oligosaccharides are the main prebiotics used to enforce formula products, so that they better promote *Bifidobacterium* spp.^{10,170–172} HMOs, besides being a major carbon source for the infant gut microbiota, were shown as a nitrogen for those same bacteria.¹⁷³ The simplest HMOs are derivatized lactoses such as galactosyl-lactoses and fucosyl and sialyllactoses. The usual composition of detected HMOs follows the formula Lx/y-z (with L: lactose; x: Gal-GlcNac disaccharide units; y: fucoses and z: sialic acids).¹⁷⁴

Nitrogen in HMOs is provided via (*N*-Acetylglucosamine) GlcNac and sialic acid.^{175,176} Neutral HMOs following this formula were detected between 8 kDa and 10 kDa which means that the majority of HMO-structures contains nitrogen with GlcNac. It was also determined that acidic HMOs of 3.5 kDa and higher provide additional nitrogen from sialic acids beyond the core GlcNac nitrogens.^{177,178} On a different resolution, the HMO lacto-*N*-tetraose (LNT) and lacto-*N*-neotetraose (LNnT) contain this nitrogen, which are, respectively, featured in Type I and Type II

HMOs.¹⁶⁷ The classification of the types is dependent on the different linkages of the GlcNAc to the galactose. Namely, β 1–3 or β 1–4 linkages, for Types I and II, respectively.¹⁷⁹ Notably, for some bacterial species, GlcNAc is even a strict requirement.¹⁸⁰ GlcNAc nitrogen is likely utilizable by more infant gut colonizers in the early stages of infancy. N-Acetylneuraminic acid (Neu5Ac) nitrogen can also prove to be a key nitrogen source as it is the predominant sialic acid in HM.^{175,181} Furthermore, HM is not only rich in HMO glycoconjugates, since other components in HM are rich in glycosylation. These can exhibit certain biological functions, digestive survival and serve, just like the indigenous host mucins, as substrates for saccharolytic bacteria. In particular, glycolipids and glycoproteins need to be considered.^{182–184}

Several bacteria thriving in the breastfed infant's gut have been shown to degrade HMOs or parts of them. This activity is thus also potentially liberating some nitrogen sources, although that specific focus is rare. They are specifically interesting because there are strong indications that HMOs reach the infant gut largely undigested. Upper-small intestinal enzymes do not have a significant impact on the HMO structure.¹⁶⁹ James *et al.* established that *Bifidobacterium breve* (*B. breve*), among many *Bifidobacterium* spp., holds the capability to degrade LNT, LNnT via different pathways.¹⁶⁷ HMO utilization by *Enterobacteriaceae* has also been studied.¹⁸⁵ The study showed that none of the *Enterobacteriaceae* strains grow on 6-siallylactose (6-SL) and LNnT. Although the potential to interact with LNnT for some infant gut bacteria is apparent, the role and effect of the included nitrogen on bacterial metabolism is clearly under established. Meanwhile, there are several bacterial species from the genus *Bacteroides* and probiotic *Akkermansia muciniphila* that have been shown to interact with LNT and LNnT.^{186,187} Since these bacteria, specifically, are promoted by breastfeeding, the relationship between the unique structure of HMOs and their prevalence is confirmed. The obvious suggestion is that HMOs are a preferred substrate for *Bifidobacterium*, meanwhile making the nutrients and the nitrogen less available for

less beneficial bacteria. The bonus of having almost exclusive access to nitrogen embedded in HMOs should not be underestimated for bacteria in an increasingly competitive infant gut.

Discussion

Although this research field is in its early stages, plenty of evidence shows that from the early onset of life, the gut microbiota is involved in catabolic and synthetic activities involving HMN. The neonatal microbiota is highly susceptible to outside influences, like the diet. This makes the early life gut microbiota a very suitable platform to study the impact of nitrogen on the microbiota and on subsequent health. This review focused on the relationship between the settling infant gut microbiota and the non-protein part of HMN. Moreover, it is becoming clear that the human host stands to benefit from this early life bacterial nitrogen cycling. We can also conclude that more data is needed, quantitatively and qualitatively, *in vivo* and *in vitro*, on an -omics scale, and through an *in-vitro* approach with early life microbiota members. Metabolomic, (meta-)proteomic and metagenomic data from clinical studies can help elucidate what the bacteria do in the infant gut, while breastfeeding ensues. For example, ever since the first attempt by Klaassens *et al.* to use metaproteomics to functionally characterize the infant gut microbiota,¹⁸⁸ meta-studies have become increasingly effective at describing bacterial activity in the gut. On the other hand, studying how important (*Bifidobacterium*) species react *in vitro* to HMN can provide evidence as well.^{34,186} This review provides further evidence on the fact that many aspects of breastfeeding are tailored to suit the infant's and gut microbiota's early life needs. The many relations between HMN and bifidobacteria can explain why the genus is successful in the infant gut.

For some nitrogen sources, bacterial species seem to have somewhat exclusive access. While for others, like urea, many of the early life symbionts of the breastfed infant have the capability to process it. As the main non-protein nitrogen source in HM, this component might prove a key metabolite in establishing the early life microbiota.

The knowledge of specific bacteria degrading and processing creatinine, creatine, or polyamines is far more elusive. For example, for creatine and creatinine metabolism genes are hardly found or described in the common infant gut symbionts. Nonetheless, both metabolites/nutrients are involved in host health and the impact of these nitrogen sources should be investigated more in depth to explain the role of HM. This will help develop formula products in such a way that they promote a health-inducing microbiota in a similar fashion. As has been hopefully indicated by this review, many of the described nitrogenous compounds can be the result of existing interspecies networks between common infant gut symbionts. Clinical studies specifically focused on dietary nitrogen and infant gut microbiota can therefore elucidate which processes matter the most *in vivo*. In contrast, future *in vitro* studies should determine if and under what conditions these bacteria produce or consume the HMN. Furthermore, future research should focus on determining if nitrogen cycling is part of metabolic interspecies networks, to what extent competition over HMN occurs and if certain interactions exist with human cells in that environment.

There is more nitrogen in HM, besides the non-protein part, there is of course bioactive protein. This review does not understate the potential importance of bioactive protein or other nitrogenous substrates in the early life diet. For example, lactoferrin (LF) is among the most detected proteins in the early life gut, indicating its availability to the microbiota and showing the potential for this (± 700 AAs) protein to have a beneficial effect in lowering pathogen colonization.^{189,190} Furthermore, products of the bacterial colonists of the infant gut could prove to be crucial vitamins. Vitamins are at the center of human health and are a product of our diet and bacterial metabolism.^{116,191} HMN could ensure that bacteria are producing vitamins at the right place and at the right time. Is that dependent on the right nitrogen source as input?

In general, the HMN supply seems fit for promoting microbial growth and making sure the gut is colonized in the early life stages. This is accomplished by the presence of GABA-shunt metabolites. The role of these free AAs in HM has once

again been confirmed. Namely, much of the early life gut symbionts seem to possess the potential to process glutamine and glutamate, the two main free AAs in HM. The free AAs seem to be there to promote general microbial growth when the gut is still relatively low on microbial mass. This nitrogen is perhaps cycled into vitamins and neurogenic compounds that can have a profound effect on the development of the infant.

Nitrogen input can steer a microbiome in a certain direction and affects the output toward a human host. Direct connections to infant health are hard to establish, however due to the function or risks of certain HMN metabolites we can hypothesize on the importance of the microbes for infant health. This review serves to establish the connections between the microbes and the HM diet and to indicate that plenty concerning nitrogen metabolism is elusive. For example, when looking at the expression levels of a *B. longum* strain in breast milk compared to glucose medium and formula, a nitrogen regulatory protein (N-II EP) *e.g.* is up-regulated,¹⁹² indicating underlying regulation and response to the presence of HMN. Determination of HMN concentrations that are suitable for infant formulas is difficult due to the lack of consensus of HM concentrations.²¹ Concentrations of HMN sources described are largely dependent on time of day, lactation stage or type, maternal diet, among others.^{193,194} Clearly, the GABA shunt and urea provide a crucial research window in studying infant gut nitrogen cycling and its relationship to bacterial survival and health. The involved metabolites surround one of the most conserved and active metabolic pathways in the infant gut, and its products are crucial for both bacterium and host.

Conclusive words

We have only just started to unravel the digestive microbial processes that lead to a healthy infant gut. It is clear, however, that much can be learned by studying the interaction between nitrogen and the settling of the infant gut microbiota. Nonetheless, the review indicates the importance of specific HMN-constituents that include urea, glutamate and polyamines for the infant gut microbiota and human health. This contradicts the major

premise that there just needs to be dietary nitrogen available through protein. However, there is a lot to be achieved mechanistically describing the importance of the composition of HMN. We have described the occurrence of dominant microbial pathways and the effects of the occurrence of these nitrogen sources on gut microbiota composition from available literature. Combined, this review provides an overview of the current relationship between HMN and the most prevalent gut symbionts during early life.

Acknowledgments

The literature review was performed by P.S.; P.S. performed the figure generation; P.S., B.S. and C.B. wrote the manuscript. The manuscript was checked by P.S. B.S., J.K. and C.B. All authors contributed to critical revisions and approved the manuscript.

Disclosure statement

B.S. and J.K. are employees of Danone Nutricia Research. P.S. and C.B. received funding from Danone Nutricia Research.

Funding

The work was supported by the Danone Nutricia Research .

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this review.

References

1. Martin R, Nauta A, Ben Amor K, Knippels L, Knol J, Garssen J. Early life: gut microbiota and immune development in infancy. *Benef Microbes*. 2010;1(4):367–382. doi:10.3920/BM2010.0027.
2. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie H, Zhong H, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host & Microbe*. 2015;17(5):690–703. doi:10.1016/j.chom.2015.04.004.
3. Goldsmith F, O'Sullivan A, Smilowitz JT, Freeman SL. Lactation and intestinal microbiota: how early diet shapes the infant gut. *J Mammary Gland Biol Neoplasia*. 2015;20(3–4):149–158. doi:10.1007/s10911-015-9335-2.

4. Rinne MM, Gueimonde M, Kalliomäki M, Hoppu U, Salminen SJ, Isolauri E. Similar bifidogenic effects of prebiotic-supplemented partially hydrolyzed infant formula and breastfeeding on infant gut microbiota. *FEMS Immunol Med Microbiol*. 2005;43(1):59–65. doi:10.1016/j.femsim.2004.07.005.
5. Yatsunen T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, et al. Human gut microbiome viewed across age and geography. *Nature*. 2012;486(7402):222. doi:10.1038/nature11053.
6. Andreas NJ, Kampmann B, Mehring Le-Doare K. Human breast milk: a review on its composition and bioactivity. *Early Hum Dev*. 2015 Nov;91(11):629–635. doi:10.1016/j.earlhumdev.2015.08.013.
7. Milani C, Duranti S, Bottacini F, Casey E, Turrone F, Mahony J, Belzer C, Delgado Palacio S, Arbolea Montes S, Mancabelli L, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. *Microbiol Mol Biol Rev*. 2017;81(4):e00036-17. doi:10.1128/MMBR.00036-17.
8. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol*. 2012;10(5):323. doi:10.1038/nrmicro2746.
9. Marcobal A, Sonnenburg JL. Human milk oligosaccharide consumption by intestinal microbiota. *Clin Microbiol Infect*. 2012;4(18 Suppl):12–15. doi:10.1111/j.1469-0691.2012.03863.x.
10. Sela DA. Bifidobacterial utilization of human milk oligosaccharides. *Int J Food Microbiol*. 2011;149(1):58–64. doi:10.1016/j.ijfoodmicro.2011.01.025.
11. Adlerberth I, Wold A. Establishment of the gut microbiota in Western infants. *Acta Paediatr*. 2009;98(2):229–238. doi:10.1111/j.1651-2227.2008.01060.x.
12. Holmes AJ, Chew YV, Colakoglu F, Cliff JB, Klaassens E, Read MN, Solon-Biet SM, McMahon AC, Cogger VC, Ruohonen K, et al. Diet-microbiome interactions in health are controlled by intestinal nitrogen source constraints. *Cell Metab*. 2017;25(1):140–151. doi:10.1016/j.cmet.2016.10.021.
13. Reese AT, Pereira FC, Schintlmeister A, Berry D, Wagner M, Hale LP, Wu A, Jiang S, Durand HK, Zhou X, et al. Microbial nitrogen limitation in the mammalian large intestine. *Nature Microbiol*. 2018 Dec;3(12):1441–1450. doi:10.1038/s41564-018-0267-7.
14. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. *Pediatric Clinics*. 2013;60(1):49–74. doi:10.1016/j.pcl.2012.10.002.
15. Harzer G, Franzke V, Bindels JG. Human milk non-protein nitrogen components: changing patterns of free amino acids and urea in the course of early lactation. *Am J Clin Nutr*. 1984;40(2):303–309. doi:10.1093/ajcn/40.2.303.

16. Carlson SE. Human milk nonprotein nitrogen: occurrence and possible functions. *Adv Pediatr.* 1985;32:43–70.
17. Carratù B, Boniglia C, Scalise F, Ambruzzi AM, Sanzini E. Nitrogenous components of human milk: non-protein nitrogen, true protein and free amino acids. *Food Chem.* 2003;81(3):357–362. doi:10.1016/S0308-8146(02)00430-2.
18. Donovan S, Lonnerdal B. Non-protein nitrogen constituents in mature human milk and colostrum. *Federation Proceedings.* 1985;44(5):7399.
19. Romain N, Dandriofosse G, Jeusette F, Forget P. Polyamine concentration in rat milk and food, human milk, and infant formulas. *Pediatr Res.* 1992;32(1):58. doi:10.1203/00006450-199207000-00011.
20. Sanguanserm Sri J, György P, Zilliken F. Polyamines in human and cow's milk. *Am J Clin Nutr.* 1974;27(8):859–865. doi:10.1093/ajcn/27.8.859.
21. Plaza-Zamora J, Sabater-Molina M, Rodríguez-Palmero M, Rivero M, Bosch V, Nadal JM, Zamora S, Larqué E. Polyamines in human breast milk for preterm and term infants. *Br J Nutr.* 2013;110(3):524–528. doi:10.1017/s0007114512005284.
22. Neville MC, Keller RP, Seacat J, Casey CE, Allen JC, Archer P. Studies on human lactation. I. Within-feed and between-breast variation in selected components of human milk. *Am J Clin Nutr.* 1984;40(3):635–646. doi:10.1093/ajcn/40.3.635.
23. Gómez-Gallego C, Morales JM, Monleón D, du Toit E, Kumar H, Linderborg K, Zhang Y, Yang B, Isolauri E, Salminen S, et al. Human breast milk NMR metabolomic profile across specific geographical locations and its association with the milk microbiota. *Nutrients.* 2018;10(10):1355. doi:10.3390/nu10101355.
24. Wang X, Gibson GR, Costabile A, Sailer M, Theis S, Rastall RA, McBain AJ. Prebiotic supplementation of in vitro fecal fermentations inhibits proteolysis by gut bacteria, and host diet shapes gut bacterial metabolism and response to intervention. *Appl Environ Microb.* 2019;85(9). e02749–18. doi:10.1128/AEM.02749-18.
25. Herrera A, Flores E, Imperial J. Nitrogen Assimilation in Bacteria. In: Schmidt, Thomas M, editor. *Encyclopedia of Microbiology.* 4th Ed. Vol. 3, Academic Press; 2019. p. 280–300. doi:10.1016/B978012/809633/820680/8.
26. Carey GB, Quinn TJ, Goodwin SE. Breast milk composition after exercise of different intensities. *J Hum Lact.* 1997;13(2):115–120. doi:10.1177/089033449701300211.
27. Gao B, Chi L, Mahbub R, Bian X, Tu P, Ru H, Lu K. multi-omics reveals that lead exposure disturbs gut microbiome development, key metabolites, and metabolic pathways. *Chem Res Toxicol.* 2017;30(4):996–1005. doi:10.1021/acs.chemrestox.6b00401.
28. Garwolińska D, Namieśnik J, Kot-Wasik A, Hewelt-Belka W. Chemistry of human breast milk—A comprehensive review of the composition and role of milk metabolites in child development. *J Agr Food Chem.* 2018;66(45):11881–11896. doi:10.1021/acs.jafc.8b04031.
29. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd RE, Doddapaneni H, Metcalf GA, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature.* 2018;562(7728):583–588. doi:10.1038/s41586-018-0617-x.
30. Xiong W, Brown CT, Morowitz MJ, Banfield JF, Hettich RL. Genome-resolved metaproteomic characterization of preterm infant gut microbiota development reveals species-specific metabolic shifts and variabilities during early life. *Microbiome.* 2017;5(1):72. doi:10.1186/s40168-017-0290-6.
31. Xiong W, Abraham PE, Li Z, Pan C, Hettich RL. Microbial metaproteomics for characterizing the range of metabolic functions and activities of human gut microbiota. *PROTEOMICS.* 2015;15(20):3424–3438. doi:10.1002/pmic.201400571.
32. Zwiittink RD, van Zoeren-Grobbe D, Martin R, van Lingen RA, Groot Jebbink LJ, Boeren S, Renes IB, van Elburg RM, Belzer C, Knol J. Metaproteomics reveals functional differences in intestinal microbiota development of preterm infants. *Molecular & Cellular Proteomics: MCP.* 2017 Sep;16(9):1610–1620. doi:10.1074/mcp.RA117.000102.
33. Cerdo T, Ruiz A, Acuna I, Jáuregui R, Jehmlich N, Haange S-B, von Bergen M, Suárez A, Campoy C. Gut microbial functional maturation and succession during human early life. *Environ Microbiol.* April 24 2018;20(6):2160–2177. doi:10.1111/1462-2920.14235.
34. Schimmel P, Kleinjans L, Bongers RS, Knol J, Belzer C. Breast milk urea as a nitrogen source for urease positive *Bifidobacterium infantis*. *FEMS Microbiol Ecol.* 2021;97(3):fiab019. doi:10.1093/femsec/fiab019.
35. George M, Nord K-E, Ronquist G, Hedenstierna G, Wiklund L. Faecal microflora and urease activity during the first six months of infancy. *Ups J Med Sci.* 1996 Jan 01;101(3):233–250. doi:10.3109/03009739609178923.
36. Fomon SJ, Matthews DE, Bier DM, Rogers RR, Rebouche CJ, Edwards BB, Nelson SE. Bioavailability of dietary urea nitrogen in the infant. *J Pediatr.* 1987;111(2):221–224. doi:10.1016/S0022-3476(87)80071-9.
37. Sela D, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, Lapidus A, Rokhsar DS, Lebrilla CB, German JB, et al. The genome sequence of *Bifidobacterium longum* subsp. *infantis* reveals adaptations for milk utilization within the infant microbiome. *PNAS.* 2008;105:18964–18969. doi:10.1073/pnas.0809584105.
38. Sumner J. The isolation and crystallisation of jack bean urease. *J Biol Chem.* 1926;69(2):435–441. doi:10.1016/S0021-9258(18)84560-4.
39. Lee MH, Pankratz HS, Wang S, Scott RA, Finnegan MG, Johnson MK, Ippolito JA, Christianson DW, Hausinger RP. Purification and

- characterization of *Klebsiella aerogenes* UreE protein: a nickel-binding protein that functions in urease metal-locenter assembly. *Protein Science*. 1993;2(6):1042–1052. doi:10.1002/pro.5560020617.
40. Belzer C, Stoof J, CS B, Kuipers EJ, Kusters JG, Van Vliet AH. Differential regulation of urease activity in *Helicobacter hepaticus* and *Helicobacter pylori*. *Microbiology*. 2005;151(12):3989–3995. doi:10.1099/mic.0.28188-0.
 41. Mora D, Arioli S, Miller V, Miller V. Microbial urease in health and disease. *PLoS Pathog*. 2014;10(12):e1004472. doi:10.1371/journal.ppat.1004472.
 42. Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. *Trends Pharmacol Sci*. 2015;36(6):395–405. doi:10.1016/j.tips.2015.03.006.
 43. Scott DR, Weeks D, Hong C, Postius S, Melchers K, Sachs G. The role of internal urease in acid resistance of *Helicobacter pylori*. *Gastroenterology*. 1998;114(1):58–70. doi:10.1016/S0016-5085(98)70633-X.
 44. Scott DR, Marcus EA, Weeks DL, Sachs G. Mechanisms of acid resistance due to the urease system of *Helicobacter pylori*. *Gastroenterology*. 2002;123(1):187–195. doi:10.1053/gast.2002.34218.
 45. Fu MS, Coelho C, De Leon-Rodriguez CM, Rossi DCP, Camacho E, Jung EH, Kulkarni M, Casadevall A, May RC. *Cryptococcus neoformans* urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH. *PLoS Pathog*. 2018;14(6):e1007144. doi:10.1371/journal.ppat.1007144.
 46. Duar RM, Kyle D, Casaburi G. Colonization resistance in the infant gut: the role of *B. infantis* in reducing pH and preventing pathogen growth. *High-Throughput*. 2020;9(2):7. doi:10.3390/ht9020007.
 47. Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. *J Pediatr*. 1978;92(5):705–712. doi:10.1016/S0022-3476(78)80133-4.
 48. Grijalva J, Vakili K. Neonatal liver physiology. *Elsevier*. 2013;2013(4):185–189. doi:10.1053/j.sempedsurg.2013.10.006.
 49. Qin Y, Cabral JM. Review properties and applications of urease. *Biocatal Biotransformation*. 2002;20(1):1–14. doi:10.1080/10242420210154.
 50. Nandi DK, Mandal S, Roy S, Pradhan S, Samanta A, Patra A, Mandal A, Das K, Sinha B. Protective role of selected probiotics on experimentally induced kidney failure in rats. *International Research Journal of Basic and Applied Sciences*. 2016;1(2):29–36.
 51. Millward DJ, Forrester T, Ah-Sing E, Yeboah N, Gibson N, Badaloo A, Boyne M, Reade M, Persaud C, Jackson A. The transfer of ¹⁵N from urea to lysine in the human infant. *Br J Nutr*. 2000;83(5):505–512. doi:10.1017/S0007114500000647.
 52. Deguchi E, Niiyama M, Kagota K, Namioka S. Role of intestinal flora on incorporation of ¹⁵N from dietary, ¹⁵N-urea, and ¹⁵N-diammonium citrate into tissue proteins in pigs. *J Nutr*. 1978;108(10):1572–1579. doi:10.1093/jn/108.10.1572.
 53. Oliveira MM, Trevilato TMB, Segura-Muñoz SI, Aragon DC, Alves LG, Nadal M, Marquès M, Domingo JL, Sierra J, Camelo JS. Essential and toxic elements in human milk concentrate with human milk lyophilizate: a preclinical study. *Environ Res*. 2020 09/1/2020;188:109733. doi:10.1016/j.envres.2020.109733.
 54. Chen YY, Weaver CA, Burne RA. Dual functions of *Streptococcus salivarius* urease. *J Bacteriol*. 2000;182(16):4667–4669. doi:10.1128/JB.182.16.4667-4669.2000.
 55. Zotta T, Ricciardi A, Rossano R, Parente E. Urease production by *Streptococcus thermophilus*. *Food Microbiol*. 2008;25(1):113–119. doi:10.1016/j.fm.2007.07.001.
 56. Crociani F, Matteuzzi D. Urease activity in the genus *Bifidobacterium*. *Annales de Microbiologie*. 1982;133(3):417–423.
 57. Sedláček I, Holochova P, Mašlaňová I, Kosina M, Spröer C, Bryndová H, Vandamme P, Rudolf I, Hubálek Z, Švec P. *Enterococcus ureilyticus* sp. nov. and *Enterococcus rotai* sp. nov., two urease-producing enterococci from the environment. *Int J Syst Evol Microbiol*. 2013;63(Pt_2):502–510. doi:10.1099/ijs.0.041152-0.
 58. D’Orazio S, Collins CM. Characterization of a plasmid-encoded urease gene cluster found in members of the family Enterobacteriaceae. *J Bacteriol*. 1993;175(6):1860–1864. doi:10.1128/jb.175.6.1860-1864.1993.
 59. Collins CM, Falkow S. Genetic analysis of *Escherichia coli* urease genes: evidence for two distinct loci. *J Bacteriol*. 1990;172(12):7138–7144. doi:10.1128/jb.172.12.7138-7144.1990.
 60. Liu X, Zhang Q, Zhou N, Tian Y. Expression of an acid urease with urethanasase activity in *E. coli* and analysis of urease gene. *Mol Biotechnol*. 2017;59(2):84–97. doi:10.1007/s12033-017-9994-x.
 61. Shin Y, Park S-J, Paek J, Kim J-S, Rhee M-S, Kim H, Kook J-K, Chang Y-H. *Bacteroides koreensis* sp. nov. and *Bacteroides kribbi* sp. nov., two new members of the genus *Bacteroides*. *Int J Syst Evol Microbiol*. 2017;67(11):4352–4357. doi:10.1099/ijssem.0.002226.
 62. Hülsemann J, Manz F, Wember T, Schöch G. Administration of creatine and creatinine with breast milk and infant milk preparations. *Klin Padiatr*. 1987;199(4):292–295. doi:10.1055/s-2008-1026805.
 63. Zuo R, Zhou S, Zuo Y, Deng Y. Determination of creatinine, uric and ascorbic acid in bovine milk and orange juice by hydrophilic interaction HPLC. *Food Chem*. 2015;182:242–245. doi:10.1016/j.foodchem.2015.02.142.
 64. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. *Physiol Rev*. 2000;80(3):1107–1213. doi:10.1152/physrev.2000.80.3.1107.
 65. Kashani K, Rosner MH, Ostermann M. Creatinine: from physiology to clinical application. *Eur J Intern Med*. 2020;72:9–14. doi:10.1016/j.ejim.2019.10.025.

66. Heimbürger O, Stenvinkel P, Bárány P. The enigma of decreased creatinine generation in acute kidney injury. *Nephrol Dial Transpl.* 2012;27(11):3973–3974. doi:10.1093/ndt/gfs459.
67. Walser M. Nutritional management of chronic renal failure. *Am J Kidney Dis.* 1982;1(5):261–275. doi:10.1016/S0272-6386(82)80024-3.
68. Mitch WE, Collier VU, Walser M. Creatinine metabolism in chronic renal failure. *Clin Sci.* 1980;58(4):327–335. doi:10.1042/cs0580327.
69. Mussap M, Noto A, Fanos V, Van Den Anker JN. Emerging biomarkers and metabolomics for assessing toxic nephropathy and acute kidney injury (AKI) in neonatology. *Biomed Res Int.* 2014;2014:1–16. doi:10.1155/2014/602526.
70. Guignard J-P. Renal function in the newborn infant. *Pediatr Clin North Am.* 1982;29(4):777–790. doi:10.1016/S0031-3955(16)34211-0.
71. Dubos R, Miller BF. The production of bacterial enzymes capable of decomposing creatinine. *J Biol Chem.* 1937;121(2):429–445. doi:10.1016/S0021-9258(18)74276-2.
72. Seifter JL. Urinary creatinine-splitting bacteria after ileal-loop diversion causing underestimate of glomerular filtration rate. *Am J Med.* 2014;127(12):e11–12. doi:10.1016/j.amjmed.2014.07.030.
73. Ienaga K, Nakamura K, Ishii A, Taga T, Miwa Y, Yoneda F. The stepwise mammalian oxidation of the hydantoin 1-methylimidazolidine-2, 4-dione into methylimidazolidinetrione via 5-hydroxy-1-methylimidazolidine-2, 4-dione. *J Chem Soc Perkin Transac.* 1989;1(66):1153–1156. doi:10.1039/p19890001153.
74. Ienaga K, Nakamura K, Yamakawa M, Toyomaki Y, Matsuura H, Yokozawa T, Oura H, Nakano K. The use of 13 C-labelling to prove that creatinine is oxidized by mammals into creatol and 5-hydroxy-1-methylhydantoin. *J Chem Soc Chem Commun.* 1991;7:509–510. doi:10.1039/c39910000509.
75. Del Chierico F, Vernocchi P, Petrucca A, Paci P, Fuentes S, Praticò G, Capuani G, Masotti A, Reddel S, Russo A, et al. Phylogenetic and metabolic tracking of gut microbiota during perinatal development. *PLoS One.* 2015;10(9):e0137347. doi:10.1371/journal.pone.0137347.
76. Suprataman H, Ismiraj RM, Mayasari N. Effects of probiotic supplementation to diets on blood urea nitrogen and plasma creatinine in broiler chicken. *Lucrări Științifice - Universitatea de Științe Agricole și Medicină Veterinară, Seria Zootehnie.* 2020;73:23–27.
77. Biswas A, Junaid N, Kumawat M, Qureshi S, Mandal A. Influence of dietary supplementation of probiotics on intestinal histo-morphometry, blood chemistry and gut health status of broiler chickens. *S Afr J Anim Sci.* 2018;48(5):968–976. doi:10.4314/sajas.v48i5.17.
78. Edison EE, Brosnan ME, Aziz K, Brosnan JT. Creatine and guanidinoacetate content of human milk and infant formulas: implications for creatine deficiency syndromes and amino acid metabolism. *Br J Nutr.* 2013;110(6):1075–1078. doi:10.1017/S000711451300010X.
79. Brosnan JT, da Silva RP, Brosnan ME. The metabolic burden of creatine synthesis. *Amino Acids.* 2011;40(5):1325–1331. doi:10.1007/s00726-011-0853-y.
80. Wyss M, Braissant O, Pischel I, Salomons GS, Schulze A, Stockler S, Walliman T. Creatine and Creatine Kinase in Health and Disease—a bright future ahead? Vol. 46. *Creatine and Creatine Kinase in Health and Disease.* 2007. p. 309–334.
81. Lee H, Slupsky CM, Heckmann AB, Christensen B, Peng Y, Li X, Hernell O, Lönnerdal B, Li Z. Milk fat globule membrane as a modulator of infant metabolism and gut microbiota: a formula supplement narrowing the metabolic differences between breastfed and formula-fed infants. *Mol Nutr Food Res.* 2021;65(3):2000603. doi:10.1002/mnfr.202000603.
82. He X, Parenti M, Grip T, Domellöf M, Lönnerdal B, Hernell O, Timby N, Slupsky CM. Publisher correction: metabolic phenotype of breast-fed infants, and infants fed standard formula or bovine MFGM supplemented formula: a randomized controlled trial. *null.* 2019;9(1):1–13. doi:10.1038/s41598-019-48858-y.
83. Ten Krooden E, Owens C. Creatinine metabolism by *Clostridium welchii* isolated from human faeces. *Experientia.* 1975;31(11):1270. doi:10.1007/BF01945773
84. Jain A, Li XH, Chen WN. An untargeted fecal and urine metabolomics analysis of the interplay between the gut microbiome, diet and human metabolism in Indian and Chinese adults. *null.* 2019 June 24;9(1):9191. doi:10.1038/s41598-019-45640-y.
85. Li N, Yan F, Wang N, Song Y, Yue Y, Guan J, Li B, Huo G. Distinct gut microbiota and metabolite profiles induced by different feeding methods in healthy Chinese infants. *Front Microbiol.* 2020 May 6;11. doi:10.3389/fmicb.2020.00714.
86. Wang M, Chen Y, Wang Y, Li Y, Zhang X, Zheng H, Ma F, Ma C, Lu B, Xie Z, et al. Beneficial changes of gut microbiota and metabolism in weaned rats with *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* Bi-07 supplementation. *J Funct Foods.* 2018;48:252–265. Sep 1. doi:10.1016/j.jff.2018.07.008.
87. Langille MG, Meehan CJ, Koenig JE, Dhanani AS, Rose RA, Howlett SE, Beiko RG. Microbial shifts in the aging mouse gut. *Microbiome.* 2014;2(1):1–12. doi:10.1186/s40168-014-0050-9.
88. Bardócz S, Duguid TJ, Brown DS, Grant G, Pusztai A, White A, Ralph A. The importance of dietary polyamines in cell regeneration and growth. *Br J Nutr.* 1995;73(6):819–828. doi:10.1079/bjn19950087.
89. Loser C, Eisel A, Harms D, Folsch UR. Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. *Gut.* 1999 Jan;44(1):12–16. doi:10.1136/gut.44.1.12.

90. Ter Steege JC, Buurman WA, Forget PP. Spermine induces maturation of the immature intestinal immune system in neonatal mice. *J Pediatr Gastroenterol Nutr.* 1997 Sep;25(3):332–340. doi:10.1097/00005176-199709000-00017.
91. Larque E, Sabater-Molina M, Zamora S. Biological significance of dietary polyamines. null. 2007 Jan;23(1):87–95. doi:10.1016/j.nut.2006.09.006.
92. Ferioli ME, Pirona L, Pinotti O. Prolactin and polyamine catabolism: specific effect on polyamine oxidase activity in rat thymus. *Mol Cell Endocrinol.* 2000 Jul 25;165(1–2):51–56. doi:10.1016/s0303-7207(00)00264-1.
93. Dandriofosse G, Peulen O, Khefif NE, Deloyer P, Dandriofosse AC, Grandfils C. Are milk polyamines preventive agents against food allergy? *Proc Nutr Soc.* 2000;59(1):81–86. doi:10.1017/s0029665100000100.
94. Gómez-Gallego C, Kumar H, García-Mantrana I, du Toit E, Suomela J-P, Linderborg KM, Zhang Y, Isolauri E, Yang B, Salminen S, et al. Breast milk polyamines and microbiota interactions: impact of mode of delivery and geographical location. *Ann Nutr Metab.* 2017;70(3):184–190. doi:10.1159/000457134.
95. Dorhout B, van Beusekom CM, Huisman M, Kingma AW, de Hoog E, Rudy Boersma E, Muskiet FAJ. Estimation of 24-hour polyamine intake from mature human milk. *J Pediatr Gastroenterol Nutr.* 1996;23(3):298–302. doi:10.1097/00005176-199610000-00015.
96. Pollack PF, Koldovský O, Nishioka K. Polyamines in human and rat milk and in infant formulas. *Am J Clin Nutr.* 1992;56(2):371–375. doi:10.1093/ajcn/56.2.371.
97. Buts J-P, De NK, De LR, Collette E, Sokal EM. Polyamine profiles in human milk, infant artificial formulas, and semi-elemental diets. *J Pediatr Gastr Nutr.* 1995;21(1):44–49. doi:10.1097/00005176-199507000-00007.
98. Milovic V. Polyamines in the gut lumen: bioavailability and biodistribution. *Eur J Gastroenterol Hepatol.* 2001;13(9):1021–1025. doi:10.1097/00042737-200109000-00004.
99. Matsumoto M, Benno Y. The relationship between microbiota and polyamine concentration in the human intestine: a pilot study. *Microbiol Immunol.* 2007;51(1):25–35. doi:10.1111/j.1348-0421.2007.tb03887.x.
100. Kibe R, Kurihara S, Sakai Y, Suzuki H, Ooga T, Sawaki E, Muramatsu K, Nakamura A, Yamashita A, Kitada Y, et al. Upregulation of colonic luminal polyamines produced by intestinal microbiota delays senescence in mice. null. 2014;4(1):4548. doi:10.1038/srep04548.
101. Tofalo R, Cocchi S, Suzzi GP, Microbiota G. Opinion. *Front Nutr.* 2019 Feb 25;6(16). doi:10.3389/fnut.2019.00016.
102. Hamana K, Matsuzaki S. Polyamines as a chemotaxonomic marker in bacterial systematics. *Crit Rev Microbiol.* 1992;18(4):261–283. doi:10.3109/10408419209113518.
103. Pegg AE, McCann PP. Polyamine metabolism and function. *Am J Physiol.* 1982 Nov;243(5):C212–21. doi:10.1152/ajpcell.1982.243.5.C212.
104. Pugin B, Barcik W, Westermann P, Heider A, Wawrzyniak M, Hellings P, Akdis CA, O'Mahony L. A wide diversity of bacteria from the human gut produces and degrades biogenic amines. *Microb Ecol Health Dis.* 2017;28(1):1353881. doi:10.1080/16512235.2017.1353881.
105. Allison C, Macfarlane GT. Influence of pH, nutrient availability, and growth rate on amine production by *Bacteroides fragilis* and *Clostridium perfringens*. *Appl Environ Microb.* 1989;55(11):2894–2898. doi:10.1128/aem.55.11.2894-2898.1989.
106. Snezhkina AV, Krasnov GS, Lipatova AV, Sadritdinova AF, Kardymon OL, Fedorova MS, Melnikova NV, Stepanov OA, Zaretsky AR, Kaprin AD, et al. The dysregulation of polyamine metabolism in colorectal cancer is associated with overexpression of c-Myc and C/EBP β rather than enterotoxigenic *Bacteroides fragilis* infection. *Oxid Med Cell Longev.* 2016;2016:1–11. doi:10.1155/2016/2353560.
107. Sakanaka M, Sugiyama Y, Kitakata A, Katayama T, Kurihara S. Carboxyspermidine decarboxylase of the prominent intestinal microbiota species *Bacteroides thetaiotaomicron* is required for spermidine biosynthesis and contributes to normal growth. *Amino Acids.* 2016 Oct;48(10):2443–2451. doi:10.1007/s00726-016-2233-0.
108. Gómez-Gallego C, Collado MC, Ilo T, Jaakkola U-M, Bernal MJ, Periago MJ, Salminen S, Ros G, Frias R. Infant formula supplemented with polyamines alters the intestinal microbiota in neonatal BALB/cOlahsd mice. *J Nutr Biochem.* Nov 1 2012;23(11):1508–1513. doi:10.1016/j.jnutbio.2011.10.003.
109. Gassen NC, Papies J, Bajaj T, Emanuel J, Dethloff F, Chua RL, Trimpert J, Heinemann N, Niemeyer C, Weege F, et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. *Nat Commun.* 2021;12(1):1–15. doi:10.1038/s41467-021-24007-w.
110. Rao JN, Xiao L, Wang J-Y. Polyamines in gut epithelial renewal and barrier function. *Physiology.* 2020;35(5):328–337. doi:10.1152/physiol.00011.2020.
111. Sugiyama Y, Nara M, Sakanaka M, Kitakata A, Okuda S, Kurihara S. Analysis of polyamine biosynthetic- and transport ability of human indigenous *Bifidobacterium*. *Biosci Biotechnol Biochem.* 2018 Sep 02;82(9):1606–1614. doi:10.1080/09168451.2018.1475211.
112. Yao X, Lu CD. Functional characterization of the potRABCD operon for spermine and spermidine uptake and regulation in *Staphylococcus aureus*. *Curr Microbiol.* 2014 Jul;69(1):75–81. doi:10.1007/s00284-014-0556-1.

113. Allison J, Kaliszewska A, Uceda S, Reiriz M, Arias N. Targeting DNA Methylation in the Adult Brain through Diet. *Nutrients*. 2021;13(11):3979. doi:10.3390/nu13113979.
114. Otaru N, Ye K, Mujezinovic D, Berchtold L, Constancias F, Cornejo FA, Krzystek A, de Wouters T, Braegger C, Lacroix C, et al. GABA production by human intestinal *Bacteroides* spp.: prevalence, regulation, and role in acid stress tolerance. *Front Microbiol*. 2021;12:860. doi:10.3389/fmicb.2021.656895.
115. Dallas DC, German JB. Enzymes in human milk. Intestinal Microbiome: Functional Aspects in Health and Disease. 2017;88:129–136.
116. Davila A-M, Blachier F, Gotteland M, Andriamihaja M, Benetti P-H, Sanz Y, Tomé D. Reprint of “Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host”. *Pharmacol Res*. 2013;69(1):114–126. doi:10.1016/j.phrs.2013.01.003.
117. Reeds PJ, Burrin DG, Stoll B, Jahoor F. Intestinal glutamate metabolism. *J Nutr*. 2000 Apr;130(4S Suppl):978s–982s. doi:10.1093/jn/130.4.978S.
118. Feehily C, Karatzas KAG. Role of glutamate metabolism in bacterial responses towards acid and other stresses. *J Appl Microbiol*. 2013;114(1):11–24. doi:10.1111/j.1365-2672.2012.05434.x.
119. van Sadelhoff JHJ, van de Heijning BJM, Stahl B, Amodio S, Rings E, Mearin M, Garssen J, Hartog A. Longitudinal variation of amino acid levels in human milk and their associations with infant gender. *Nutrients*. Sep 5 2018;10(9):1233. doi:10.3390/nu10091233.
120. Koletzko B. Glutamate supply and metabolism in infants. *Ann Nutr Metab*. 2018;73(suppl 55):29–35. doi:10.1159/000494780.
121. Van Sadelhoff JH, Wiertsema SP, Garssen J, Hogenkamp A. Free amino acids in human milk: a potential role for glutamine and glutamate in the protection against neonatal allergies and infections. *Front Immunol*. 2020;11:1007. doi:10.3389/fimmu.2020.01007.
122. Lonnerdal B. Infant formula and infant nutrition: bioactive proteins of human milk and implications for composition of infant formulas. *Am J Clin Nutr*. 2014 Mar;99(3):712s–717s. doi:10.3945/ajcn.113.071993.
123. Woods DR, Reid SJ. Recent developments on the regulation and structure of glutamine synthetase enzymes from selected bacterial groups. *FEMS Microbiol Rev*. 1993;11(4):273–283. doi:10.1111/j.1574-6976.1993.tb00001.x.
124. Petroff OA. GABA and glutamate in the human brain. *The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry*. 2002 Dec 8(6):562–573. doi:10.1177/1073858402238515
125. Boonstra E, de Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Mini Review. *Front Psychol*. 2015 Oct 06;6(1520). doi:10.3389/fpsyg.2015.01520.
126. Mazzoli R, Pessione E. The Neuro-endocrinological role of microbial glutamate and GABA signaling. *Frontiers Microbiol*. 2016;7:1934. doi:10.3389/fmicb.2016.01934.
127. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, Liu Y, Cheng K, Zhou C, Wang H, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. *Sci Adv*. 2019;5(2):eaau8317. doi:10.1126/sciadv.aau8317.
128. van den Heuvel RH, Svergun DI, Petoukhov MV, Coda A, Curti B, Ravasio S, Vanoni MA, Mattevi A. The active conformation of glutamate synthase and its binding to ferredoxin. *J Mol Biol*. 2003;330(1):113–128. doi:10.1016/S0022-2836(03)00522-9.
129. Watford M, Reeds PJ. Glutamate metabolism in the gut. *Forum Nutr*. 2003;56:81–82.
130. Hatanaka M, Tachiki T, Kumagai H, Tochikura T. Distribution and some properties of glutamine synthetase and glutamate dehydrogenase in bifidobacteria. *Agric Biol Chem*. 1987;51(1):251–252. doi:10.1080/00021369.1987.10868009.
131. Hatanaka M, Tachiki T, Furukawa R, Tochikura T. Purification and some properties of glutamine synthetases from bifidobacteria. *Agric Biol Chem*. 1987;51(2):425–433. doi:10.1080/00021369.1987.10868070.
132. Bortoluzzi C, Rochell S, Applegate T. Threonine, arginine, and glutamine: influences on intestinal physiology, immunology, and microbiology in broilers. *Poult Sci*. 2018;97(3):937–945. doi:10.3382/ps/pex394.
133. Mamuad LL, Lee SS. The role of glutamic acid-producing microorganisms in rumen microbial ecosystems. *Journal of Life Science*. 2021;31:520–526.
134. Camperchioli DW, Bush SP, Slonczewski J. GABA production through acid resistance mechanisms in *Escherichia coli*. *Kenyon Summer Science Scholars Program*. 2015. Paper 5.
135. Kim ES, Kim JS, Cho KH, Lee KH, Tamari Y. 1998. Quantitation of taurine and selenium levels in human milk and estimated intake of taurine by breast-fed infants during the early periods of lactation. Vol. 3pp. 477–486. *Adv Exp Med Biol*.
136. Agostoni C, Carratu B, Boniglia C, Riva E, Sanzini E. Free amino acid content in standard infant formulas: comparison with human milk. *J Am Coll Nutr*. 2000;19(4):434–438. doi:10.1080/07315724.2000.10718943.
137. Ridlon JM, Wolf PG, Gaskins HR. Taurocholic acid metabolism by gut microbes and colon cancer. *Gut Microbes*. 2016;7(3):201–215. doi:10.1080/19490976.2016.1150414.
138. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. *Curr Opin Gastroenterol*. 2014;30(3):332. doi:10.1097/MOG.0000000000000057.

139. Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res.* 2006;47(2):241–259. doi:10.1194/jlr.R500013-JLR200.
140. Xing M, Wei Y, Hua G, Li M, Nanjaraj Urs AN, Wang F, Hu Y, Zhai W, Liu Y, Ang EL, et al. A gene cluster for taurine sulfur assimilation in an anaerobic human gut bacterium. *Biochem J.* 2019;476(15):2271–2279. doi:10.1042/BCJ20190486.
141. van der Ploeg JR, Eichhorn E, Leisinger T. Sulfonate-sulfur metabolism and its regulation in *Escherichia coli*. *Arch Microbiol.* 2001;176(1–2):1–8. doi:10.1007/s002030100298.
142. Uria-Nickelsen MR, Leadbetter ER, Godchaux W III. Sulphonate utilization by enteric bacteria. *Microbiology.* 1993;139(2):203–208. doi:10.1099/00221287-139-2-203.
143. Xing M, Wei Y, Zhou Y, Zhang J, Lin L, Hu Y, Hua G, Nanjaraj Urs AN, Liu D, Wang F, et al. Radical-mediated CS bond cleavage in C2 sulfonate degradation by anaerobic bacteria. *Nat Commun.* 2019;10(1):1–11. doi:10.1038/s41467-019-09618-8.
144. Collard J-M, Sansonetti P, Papon N. Taurine makes our microbiota stronger. *Trends in Endocrinol Metabolism.* 2021;32(5):259–261. doi:10.1016/j.tem.2021.02.006.
145. Stacy A, Andrade-Oliveira V, McCulloch JA, Hild B, Oh JH, Perez-Chaparro PJ, Sim CK, Lim AI, Link VM, Enamorado M, et al. Infection trains the host for microbiota-enhanced resistance to pathogens. *Cell.* 2021;184(3):615–627. e17. doi:10.1016/j.cell.2020.12.011.
146. Cook AM, Denger K. Metabolism of Taurine in Microorganisms. *Adv Exp Med Biol.* 2006. pp. 3–13.
147. Yao L, Seaton SC, Ndousse-Fetter S, Adhikari AA, DiBenedetto N, Mina AI, Banks AS, Bry L, Devlin AS. A selective gut bacterial bile salt hydrolase alters host metabolism. *Elife.* 2018;7:e37182. doi:10.7554/eLife.37182.
148. Arrieta M-C, Arévalo A, Stiemsma L, Dimitriu P, Chico ME, Loor S, Vaca M, Boutin RCT, Morien E, Jin M, et al., Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting, *J Allergy Clin Immunol.* 2018;142(2):424–434.e10. 2019 Sep 6. doi:10.1016/j.jaci.2017.08.041.
149. Shoveller AK, Stoll B, Ball RO, Burrin DG. Nutritional and functional importance of intestinal sulfur amino acid metabolism. *J Nutr.* 2005;135(7):1609–1612. doi:10.1093/jn/135.7.1609.
150. Mihara H, Esaki N. Bacterial cysteine desulfurases: their function and mechanisms. *Appl Microbiol Biotechnol.* 2002 Oct;60(1–2):12–23. doi:10.1007/s00253-002-1107-4.
151. Ferrario C, Duranti S, Milani C, Mancabelli L, Lugli GA, Turroni F, Mangifesta M, Viappiani A, Ossiprandi MC, van Sinderen D, et al. Exploring Amino Acid Auxotrophy in *Bifidobacterium bifidum* PRL2010. *Front Microbiol.* 2015;6:1331. doi:10.3389/fmicb.2015.01331.
152. Ferrario C, Duranti S, Milani C, Mancabelli L, Lugli GA, Turroni F, Mangifesta M, Viappiani A, Ossiprandi MC, van Sinderen D, et al. Exploring amino acid auxotrophy in *Bifidobacterium bifidum* PRL2010. *Front Microbiol.* 2015;6:1331. doi:10.3389/fmicb.2015.01331.
153. Circu ML, Aw TY. Intestinal redox biology and oxidative stress. Elsevier. 2012;2012(7):729–737. doi:10.1016/j.semcd.2012.03.014.
154. Lamattina L, Garcia-Mata C, Graziano M, Pagnussat G. Nitric oxide: the versatility of an extensive signal molecule. *Annu Rev Plant Biol.* 2003;54(1):109–136. doi:10.1146/annurev.arplant.54.031902.134752.
155. Sobko T, Reinders CI, Jansson E, Norin E, Midtvedt T, Lundberg JO. Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite. *Nitric Oxide: Biol & Chem.* 2005 Dec;13(4):272–278. doi:10.1016/j.niox.2005.08.002.
156. Iizuka T, Sasaki M, Oishi K, Uemura S, Koike M, Minatogawa Y. Nitric oxide may trigger lactation in humans. *J Pediatr.* 12/1/1997 1997;131(6):839–843. doi:10.1016/S0022-3476(97)70030-1.
157. Ohta N, Tsukahara H, Ohshima Y, Nishii M, Ogawa Y, Sekine K, Kasuga K, Mayumi M. Nitric oxide metabolites and adrenomedullin in human breast milk. *Early Hum Dev.* 06/1/2004 2004;78(1):61–65. doi:10.1016/j.earlhumdev.2004.04.002.
158. Yuksel S, Yigit AA, Cinar M, Atmaca N, Onaran Y. Oxidant and antioxidant status of human breast milk during lactation period. *Dairy Sci Technol.* 2015;95(3):295–302. doi:10.1007/s13594-015-0211-z.
159. Stevens CR, Millar TM, Clinch JG, Kanczler JM, Bodamyali T, Blake DR. Antibacterial properties of xanthine oxidase in human milk. *Lancet.* 09/2/2000 2000;356(9232):829–830. doi:10.1016/S0140-6736(00)02660-X.
160. Fang FC, Vázquez-Torres A. Reactive nitrogen species in host–bacterial interactions. *Curr Opin Immunol.* 2019 10/1/2019;60:96–102. doi:10.1016/j.coi.2019.05.008.
161. Bartholomew B, Hill MJ. The pharmacology of dietary nitrate and the origin of urinary nitrate. *Food Chem Toxicol.* 1984 Oct;22(10):789–795. doi:10.1016/0278-6915(84)90116-9.
162. Tiso M, Schechter AN. Nitrate reduction to Nitrite, Nitric Oxide and Ammonia by Gut Bacteria under Physiological Conditions. *PLoS One.* 2015;10(3):e0119712. doi:10.1371/journal.pone.0119712.
163. Uden G, Bongaerts J. Alternative respiratory pathways of *Escherichia coli*: energetics and transcriptional regulation in response to electron acceptors. *Biochimica et Biophysica Acta (BBA) - Bioenergetics.* 07/4/1997 1997;1320(3):217–234. doi:10.1016/S0005-2728(97)00034-0.
164. Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants' and

- children's health? *J Pediatr Gastr Nutr.* 2015;60(3):294–307. doi:10.1097/MPG.0000000000000597.
165. Jost T, Lacroix C, Braegger CP, Chassard C, Ravel J. New insights in gut microbiota establishment in healthy breast fed neonates. *PLoS One.* 2012;7(8):e44595. doi:10.1371/journal.pone.0044595.
166. Sparacino-Watkins C, Stolz JF, Basu P. Nitrate and periplasmic nitrate reductases. *Chem Soc Rev.* Jan 21 2014;43(2):676–706. doi:10.1039/c3cs60249d.
167. James K, Motherway MOC, Bottacini F, van Sinderen D. *Bifidobacterium breve* UCC2003 metabolises the human milk oligosaccharides lacto-N-tetraose and lacto-N-neotetraose through overlapping, yet distinct pathways. *2016*;6(1):1–16. doi:10.1038/srep38560.
168. Petschow BW, Talbott RD. Response of *Bifidobacterium* species to growth promoters in human and cow milk. *Pediatr Res.* 1991;29(2):208–213. doi:10.1203/00006450-199102000-00021.
169. Engfer MB, Stahl B, Finke B, Sawatzki G, Daniel H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. *Am J Clin Nutr.* 2000;71(6):1589–1596. doi:10.1093/ajcn/71.6.1589.
170. Jantscher-Krenn E, Bode L. Human milk oligosaccharides and their potential benefits for the breast-fed neonate. *Minerva Pediatr.* 2012;64:83–99.
171. Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. *Trends Microbiol.* 2010;18(7):298–307. doi:10.1016/j.tim.2010.03.008.
172. Vandenplas Y, Berger B, Carnielli VP, Ksiazyk J, Lagström H, Sanchez Luna M, Migacheva N, Mosselmans J-M, Picaud J-C, Possner M, et al. Human milk oligosaccharides: 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) in infant formula. *Nutrients.* 2018;10(9):1161. doi:10.3390/nu10091161.
173. Le Parc A, Dallas DC, Duaut S, Leonil J, Martin P, Barile D. Characterization of goat milk lactoferrin N-glycans and comparison with the N-glycomes of human and bovine milk. *Electrophoresis.* 2014;35(11):1560–1570. doi:10.1002/elps.201300619.
174. Bahr U, Karas M. Differentiation of 'isobaric' peptides and human milk oligosaccharides by exact mass measurements using electrospray ionization orthogonal time-of-flight analysis. *Rapid Commun Mass Sp.* 1999;13(11):1052–1058. doi:10.1002/(SICI)1097-0231(19990615)13:11<1052:AID-RCM604>3.0.CO;2-Y.
175. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology.* 2012;22(9):1147–1162. doi:10.1093/glycob/cws074.
176. Wu S, Grimm R, German JB, Lebrilla CB. Annotation and structural analysis of sialylated human milk oligosaccharides. *J Proteome Res.* 2011;10(2):856–868. doi:10.1021/pr101006u.
177. Stahl B, Thurl S, Zeng J, Karas M, Hillenkamp F, Steup M, Sawatzki G. Oligosaccharides from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. *Anal Biochem.* 1994;223(2):218–226. doi:10.1006/abio.1994.1577.
178. Finke B, Stahl B, Pfenninger A, Karas M, Daniel H, Sawatzki G. Analysis of high-molecular-weight oligosaccharides from human milk by liquid chromatography and MALDI-MS. *Anal Chem.* 1999;71(17):3755–3762. doi:10.1021/ac990094z.
179. Ruhaak LR, Lebrilla CB. Advances in analysis of human milk oligosaccharides. *Advances in Nutrition.* 2012;3(3):406S–414S. doi:10.3945/an.112.001883.
180. van der Ark KC, Aalvink S, Suarez-diez M, Schaap PJ, de Vos WM, Belzer C. Model-driven design of a minimal medium for *Akkermansia muciniphila* confirms mucus adaptation. *Microb Biotechnol.* 2018;11(3):476–485. doi:10.1111/1751-7915.13033.
181. Dallas DC, Martin WF, Strum JS, Zivkovic AM, Smilowitz JT, Underwood MA, Affolter M, Lebrilla CB, German JB. N-linked glycan profiling of mature human milk by high-performance microfluidic chip liquid chromatography time-of-flight tandem mass spectrometry. *J Agr Food Chem.* 2011;59(8):4255–4263. doi:10.1021/jf104681p.
182. Georgi G, Bartke N, Wiens F, Stahl B. Functional glycans and glycoconjugates in human milk. *Am J Clin Nutr.* 2013;98(2):578S–585S. doi:10.3945/ajcn.112.039065.
183. Zhu J, Lin Y-H, Dingess KA, Mank M, Stahl B, Heck AJ. Quantitative longitudinal inventory of the N-glycoproteome of human milk from a single donor reveals the highly variable repertoire and dynamic site-specific changes. *J Proteome Res.* 2020;19(5):1941–1952. doi:10.1021/acs.jproteome.9b00753.
184. Dingess KA, Li C, Zhu J. Human milk proteome: what's new? *Current Opinion in Clinical Nutrition & Metabolic Care.* 2021;24(3):252–258. doi:10.1097/MCO.0000000000000742.
185. Hoeflinger JL, Davis SR, Chow J, Miller MJ. In vitro impact of human milk oligosaccharides on *Enterobacteriaceae* growth. *J Agr Food Chem.* 2015;63(12):3295–3302. doi:10.1021/jf505721p.
186. Kostopoulos I, Elzinga J, Ottman N, Klievink JT, Blijenberg B, Aalvink S, Boeren S, Mank M, Knol J, de Vos WM, et al. *Akkermansia muciniphila* uses human milk oligosaccharides to thrive in the early life conditions in vitro. *2020*;10(1):1–17. doi:10.1038/s41598-020-71113-8.
187. Chia LW, Mank M, Blijenberg B, Aalvink S, Bongers RS, Stahl B, Knol J, Belzer C. *Bacteroides thetaiotaomicron* fosters the growth of butyrate-producing *Anaerostipes caccae* in the presence of lactose and total human milk carbohydrates. *Microorganisms.* 2020;8(10):1513. doi:10.3390/microorganisms8101513.
188. Klaassens ES, De Vos WM, Vaughan EE. Metaproteomics approach to study the functionality of the microbiota in the human infant

- gastrointestinal tract. *Appl Environ Microb.* **2007**;73(4):1388–1392. doi:10.1128/AEM.01921-06.
189. Young JC, Pan C, Adams RM, Brooks B, Banfield JF, Morowitz MJ, Hettich RL. Metaproteomics reveals functional shifts in microbial and human proteins during a preterm infant gut colonization case. *PROTEOMICS.* **2015**;15(20):3463–3473. doi:10.1002/pmic.201400563.
190. Villavicencio A, Rueda MS, Turin CG, Ochoa TJ. Factors affecting lactoferrin concentration in human milk: how much do we know? *Biochemistry and cell biology = Biochimie et biologie cellulaire.* **2017**;95(1):12–21. doi:10.1139/bcb-2016-0060.
191. Gu Q, Li P. Probiotics and Prebiotics in Human Nutrition and Health. Biosynthesis of Vitamins by Probiotic Bacteria. **2016**. doi:10.5772/63117.
192. González R, Klaassens ES, Malinen E, de Vos WM, Vaughan EE. Differential transcriptional response of *Bifidobacterium longum* to human milk, formula milk, and galactooligosaccharide. *Appl Environ Microb.* **2008**;74(15):4686–4694. doi:10.1128/aem.00122-08.
193. Thurl S, Munzert M, Henker J, Boehm G, Müller-Werner B, Jelinek J, Stahl B. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *Br J Nutr.* **2010**;104(9):1261–1271. doi:10.1017/S0007114510002072.
194. Italianer MF, Naninck EF, Roelants JA, van der Horst GTJ, Reiss IKM, Goudoever JBV, Joosten KFM, Chaves I, Vermeulen MJ. Circadian variation in human milk composition, a systematic review. *Nutrients.* **2020**;12(8):2328. doi:10.3390/nu12082328.